MA
Mohammed Ameen Abdul Salam
About Mohammed Ameen Abdul Salam
Data last updated:
Mohammed Ameen Abdul Salam is a Director at Absal Pharma Global Private Limited (since 2020) and Designated Partner at Medzolaze Pharma Llp (since 2021). The companies operate in Chemicals and Business Services. The largest current company by reported revenue is Absal Pharma Global Private Limited at ₹28.6 Lakh (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 25 Dec 2020 | 2020 | ₹28.6 Lakh (FY 2024) | Active | |
| Designated Partner | 01 Nov 2021 | 2021 | Active |
Board colleagues of Mohammed Ameen Abdul Salam
| Name | DIN | Company | Designation |
|---|---|---|---|
| Abdulsalam Abdulrahuman Kunju | 09010139 | Absal Pharma Global Private Limited , Medzolaze Pharma Llp | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Mohammed Ameen Abdul Salam
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mohammed Ameen Abdul Salam
Mohammed Ameen Abdul Salam currently holds 2 directorships: Absal Pharma Global Private Limited (Director, since 25 Dec 2020, revenue ₹28.6 Lakh (FY 2024)); Medzolaze Pharma Llp (Designated Partner, since 01 Nov 2021).
Mohammed Ameen Abdul Salam was first appointed on 25 Dec 2020 as Director at Absal Pharma Global Private Limited. The most recent appointment on record is 01 Nov 2021 at Medzolaze Pharma Llp.
The current boards of Mohammed Ameen Abdul Salam's companies include Abdulsalam Abdulrahuman Kunju (Absal Pharma Global Private Limited).